Figure 6:
(A) SNR measurements normalized to peak intensity at 5 minutes post-injection for FOLFIRINOX-treated PDAC. Plotted lines represent Gd-DOTA (black) and CM-101 (red) signal loss over 25 minutes. Relative to peak signal, the MR signal intensity is significantly greater with CM-101 compared to Gd-DOTA from 10–25 minutes. Difference in AUC5–25 is graphically displayed by solid gray background. AUC5–25 for Gd-DOTA and CM-101 are shown in the bar graph. (B) Relative MR signal attenuation in surrounding pancreatic tissue up to 25 minutes post injection with CM-101 and Gd-DOTA after FOLFIRINOX treatment. AUC5–25 for Gd-DOTA and CM-101 are shown in the bar graph. (C) ICP-MS quantitation of Eu-DOTA and CM-101 probe uptake in muscle, PDAC, and pancreas tissues 25 minutes after tail vein injection in FOLFIRINOX-treated mice. (D) Representative axial images of untreated PDAC 5 and 25 minutes after CM-101 injection. Tumor is outlined in white (grayscale) and white arrows point to fibrotic tumor regions. Retention map displays MR signal intensity normalized to peak signal at 5 minutes in tumor tissue. (E) Representative axial images of FOLFIRINOX-treated PDAC 5 and 25 minutes after CM-101 injection with retention map. (F) CM-101-based MR signal intensity measurements normalized to peak intensity at 5 minutes. Plotted lines represent untreated (black) and FOLFIRINOX-treated (blue) PDAC signal loss over 25 minutes. Difference in AUC5–25 is graphically displayed by solid gray background. AUC5–25 for CM-101 in untreated and FOLFIRINOX-treated PDAC are shown in the bar graph. ICP-MS quantitation of (G) tumor and (I) pancreatic tissue CM-101 probe uptake 25 minutes after tail vein injection. (H) CM-101 MR signal intensity measurements for pancreatic tissue in untreated and FOLFIRINOX-treated mice, and associated AUC5–25 calculations. * p < 0.05; ** p < 0.01.